Muhammed A. Moukhtar Hammad, MBBCh, on testosterone therapy and risk of hearing loss

Testosterone replacement therapy (TRT) was not associated with an increased risk of hearing loss in hypogonadal men, according to data presented at the 26th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America in Grapevine, Texas.¹

In an interview with Urology Times®, presenting author Muhammed A. Moukhtar Hammad, MBBCh, of the University of California, Irvine, outlined the background and key results from the study.

For the study, the investigators retrospectively compared 107,908 patients who received TRT with 107,908 patients who never received TRT. All patients had a diagnosis of hypogonadism and no prior history of ear disorders. According to the authors, "The mean follow-up was 4.45 ± 3.78 years for TRT users and 4.32 ± 3.79 years for non-users."

Overall, matched comparison data showed that the incidence of ear disorders was 3.14% in the TRT group vs 3.279% in the non-TRT group, which was not found to be statistically significant (P = .0669; SD= 0.0079).

REFERENCE

1. Hammad MAM, Shahait M, Chawareb A, et al. Testosterone replacement therapy and risk of hearing loss in hypogonadal men: A matched cohort study using a global EHR network. Presented at: 26^th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America. October 9-12, 2025. Grapevine, Texas. Abstract 273